Alectinib, a next generation tyrosine kinase inhibitor found to improve the symptoms associated with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer than with the standard treatment of crizotinib.
from Medindia Health News https://ift.tt/2IPcVQe
No comments:
Post a Comment